Literature DB >> 8574315

Combined-modality treatment of adductor spasmodic dysphonia with botulinum toxin and voice therapy.

T Murry1, G E Woodson.   

Abstract

A combined-modality treatment program consisting of botulinum toxin injection (Botox) and voice therapy was used to treat 17 subjects diagnosed with adductor spasmodic dysphonia (ADD SD). Ten subjects with ADD SD served as the control and were given Botox only. Voice therapy after Botox injection was directed toward reducing the hyperfunctional vocal behaviors, primarily glottal overpressure at voice onset and anterior-posterior squeezing. The results indicated that subjects who underwent combined-modality treatment maintained significantly higher mean airflow rates for significantly longer periods. Moreover, there was a carryover effect in these patients when they received Botox only. Adductor spasmodic dysphonia is treated most effectively when intrinsic laryngeal muscle spasms are reduced or eliminated by Botox injection and extrinsic hyperfunctional vocal behaviors are treated with voice therapy.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8574315     DOI: 10.1016/s0892-1997(05)80211-5

Source DB:  PubMed          Journal:  J Voice        ISSN: 0892-1997            Impact factor:   2.009


  7 in total

1.  Acoustic Model of Perceived Overall Severity of Dysphonia in Adductor-Type Laryngeal Dystonia.

Authors:  Daniel P Buckley; Manuel Diaz Cadiz; Tanya L Eadie; Cara E Stepp
Journal:  J Speech Lang Hear Res       Date:  2020-07-16       Impact factor: 2.297

2.  Temporal specificity of abnormal neural oscillations during phonatory events in laryngeal dystonia.

Authors:  Hardik Kothare; Sarah Schneider; Danielle Mizuiri; Leighton Hinkley; Abhishek Bhutada; Kamalini Ranasinghe; Susanne Honma; Coleman Garrett; David Klein; Molly Naunheim; Katherine Yung; Steven Cheung; Clark Rosen; Mark Courey; Srikantan Nagarajan; John Houde
Journal:  Brain Commun       Date:  2022-02-11

3.  Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.

Authors:  D M Simpson; A Blitzer; A Brashear; C Comella; R Dubinsky; M Hallett; J Jankovic; B Karp; C L Ludlow; J M Miyasaki; M Naumann; Y So
Journal:  Neurology       Date:  2008-05-06       Impact factor: 9.910

Review 4.  Research priorities in spasmodic dysphonia.

Authors:  Christy L Ludlow; Charles H Adler; Gerald S Berke; Steven A Bielamowicz; Andrew Blitzer; Susan B Bressman; Mark Hallett; H A Jinnah; Uwe Juergens; Sandra B Martin; Joel S Perlmutter; Christine Sapienza; Andrew Singleton; Caroline M Tanner; Gayle E Woodson
Journal:  Otolaryngol Head Neck Surg       Date:  2008-10       Impact factor: 3.497

5.  Guidelines for the use of botulinum toxin in movement disorders and spasticity.

Authors:  Afshan Jabeen; Rukmini M Kandadai; Meena A Kannikannan; Rupam Borgohain
Journal:  Ann Indian Acad Neurol       Date:  2011-07       Impact factor: 1.383

Review 6.  Speech-Language Pathology Evaluation and Management of Hyperkinetic Disorders Affecting Speech and Swallowing Function.

Authors:  Julie M Barkmeier-Kraemer; Heather M Clark
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2017-09-21

Review 7.  Botulinum toxin injections for the treatment of spasmodic dysphonia.

Authors:  C C W Watts; R Whurr; C Nye
Journal:  Cochrane Database Syst Rev       Date:  2004
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.